SENESCENCE2030: Targeting Cell Senescence to Prevent Age-Related Diseases

Preventing or alleviating aging associated diseases, collectively rather than individually, is the challenge to extend the human healthspan.

The knowledge on cellular and molecular mechanisms identified so far as “hallmarks of aging” allow experimental strategies to prevent aging anticipation and extend the healthspan. A body of evidence indicate that cell senescence is a targetable hallmark of aging, typically associated with metabolic disorders, cardiovascular diseases, neurodegeneration and cancer.

The Action SENESCENCE2030 aims at rooting in Europe the vision of cells senescence and its targeting at center for the prevention of aging related disorders.

Through the engagement with international partners, SENESCENCE2030 generates an interdisciplinary and intersectoral network of experts in geroscience and senescence, facilitating the acquisition of new skills and knowledge among young researchers, medical personnel and innovators from Inclusiveness Target Countries.

SENESCENCE2030 goes beyond the state-of-the-art by opening vibrant knowledge exchange on senescence and senotherapy, trying to overcome the difficulties that prevent in Europe the clinical application of these knowledge for the identification of feasible diagnostics paths, more efficient clinical trials, and effective interventions on lifestyle and nutrition.

SENESCENCE2030 will highlight the socio-economic impact of therapeutic approaches and cost-effectiveness of timing interventions to define innovative processes, measures and products of impact on industries, funders and policy makers interested in addressing healthcare and socioeconomic challenges related to the aging.

Overall, SENESCENCE2030 will empower the transition from a disease-centered therapeutic approach to a balanced preventive and personalized treatment to avoid aging anticipation and promote individuals healthspan extension for the next decade